. Author manuscript; available in PMC: 2013 Jul 1.

Published in final edited form as: Biochem Pharmacol. 2012 Aug 28;85(1):1–11. doi: 10.1016/j.bcp.2012.08.018

Table 3.

Clinical studies of gene targeting in Ischemic Heart Disease utilizing viral vectors

Reference	Trial/Design	Number of Patients	Therapeutic Agent	Delivery	Endpoints	Outcomes	Major Adverse Events
[56]	Phase I	21	AdV-VEGF-A₁₂₁	Intramyocardial injections	CCS; NTG/week	Improvement trend; Improvement trend	None

[57]	AGENT RCT	79	AdV-FGF-4	Intracoronary infusion	Stress-induced Wall Motion;	No change;	None
					ETT	Improved

[58]	AGENT-2 RCT	52	AdV-FGF-4	Intracoronary infusion	Perfusion Defect Size;	No change	None
					Angina/week;	No change
					NTG/week	No change

[59]	KAT Phase II	103	AdV-VEGF-A₁₆₅ vs VEGF-A₁₆₅ (plasmid)	Intracoronary infusion	Myocardial perfusion (SPECT); CCS	Improved (AdV), No change (plasmid); No change (AdV & plasmid)	Death (n=1), Transient fever (n=19, Adv; n=11, plasmid)

[60]	REVASC Phase II	67	AdV-VEGF-A₁₂₁	Intramyocardial injection—mini-thoracotomy	Myocardial perfusion (SPECT);	No change;	Death (n=1)
					CCS	Improved

[61]	AGENT-3 & AGENT-4 RCT	532	AdV-FGF-4	Intracoronary infusion	ETT; CCS;	No change; Improved(gender bias);	None
					Angina/week; NTG/week	No change; No change

AdV, adenoviral vector; VEGF, vascular endothelial growth factor; CCS, Canadian Cardiovascular Society functional classification of angina; NTG, nitroglycerine tablets; RCT, randomized controlled trial; FGF, fibroblast growth factor; ETT, exercise tolerance time; CK, creatine kinase; SPECT, single photon emission computerized tomography